drugset
drugset / Trial / NCT04676178

A Study of PRA023 in Healthy Volunteers

NCT04676178 ↗

Phase 1 Completed 69 enrolled Prometheus Biosciences, Inc. Celerion · collab
RandomizedSequentialDouble-blindBasic science

Summary

This is randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PRA023 in healthy volunteers.

Timeline

Start
2020-12-15
Primary completion
2021-09-23
Completion
2021-09-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Tulisokibart Monoclonal antibody — Intravenous

Indications

No indication recorded.